Wave Life Sciences Ltd., a clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform. The company's RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. It is developing WVE-006, an RNA editing oligonucleotide for the treatment of alpha-1 antitrypsin deficiency; WVE-007, a GalNAc-conjugated small interfering RNA designed to silence INHBE mRNA targeting obesity; WVE-N531, an exon skipping oligonucleotide for the treatment of Duchenne muscular dystrophy; and WVE-003, an allele-selective oligonucleotide for the treatment of Huntington's disease (HD). The company has collaboration agreements with GlaxoSmithKline for the research, development, and commercialization of oligonucleotide therapeutics; Takeda Pharmaceutical Company Limited for the research, development, and commercialization of oligonucleotide therapeutics for disorders of the Central Nervous System; and Asuragen, Inc. for the development and potential commercialization of companion diagnostics for investigational allele-selective therapeutic programs targeting HD. Wave Life Sciences Ltd. was incorporated in 2012 and is based in Singapore.

Wave Life Sciences Ltd.

High‑risk, high‑reward stocks are companies whose share prices can witness large swings, either up or down, as their future is uncertain. However, ...

3 High-Risk, High-Reward Stocks to Buy Now for Explosive Upside, According to Analysts – 5/22/26

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Relay Therapeutics (RLAY) and Wave Life Sciences (WV...

Analysts Offer Insights on Healthcare Companies: Relay Therapeutics (RLAY) and Wave Life Sciences (WVE)

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Wave Life Sciences (WVE), Gossamer Bio (GOSS) and ...

Analysts Offer Insights on Healthcare Companies: Wave Life Sciences (WVE), Gossamer Bio (GOSS) and Cullinan Management (CGEM)

Wave Life Sciences ( ($WVE) ) has issued an announcement. On May 18, 2026, Wave Life Sciences reported updated data from its ongoing RestorAATion-2...

Wave Life Sciences advances WVE-006 RNA editing trial

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Tenaya Therapeutics (TNYA) and Wave Life Sciences (W...

Wall Street Analysts Are Bullish on Top Healthcare Picks

Wave Life Sciences Pte. Ltd (($WVE)) has held its Q1 earnings call. Read on for the main highlights of the call. Wave Life Sciences’ latest earning...

Wave Life Sciences Signals Momentum In Earnings Call

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Spyre Therapeutics (SYRE), AxoGen (AXGN) and Wave Li...

Analysts’ Top Healthcare Picks: Spyre Therapeutics (SYRE), AxoGen (AXGN)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on NeoGenomics (NEO) and Wave Life Sciences (WVE) with ...

Wave Life Sciences ( ($WVE) ) has shared an announcement. On April 28, 2026, Wave Life Sciences reported first quarter 2026 results and highlighted...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	WVE	$6.38	0.00%	2.44M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	WVE	$6.38	0%	2.44M
3
4
5
6

WVE

WVE

Get Wave Life Sciences Ltd. Data in Excel

Get Wave Life Sciences Ltd. Data in Excel